Loading clinical trials...
Loading clinical trials...
Predictors of Response After Induction Therapy With TNF-alpha Inhibitor in Inflammatory Bowel Disease, Comparison to Normal
A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease composed of two types: Crohn's disease (CD) and ulcerative colitis (UC). It is difficult to cure the IBD completely and patients with clinical or endoscopic remission can worsen again. Therefore, predicting the prognosis of patients with IBD is still challenging. Endoscopic biopsied samples and blood samples from IBD patients and non-IBD controls have been collected and the expression levels of multiple markers which are associated with disease activity and severity will be assessed. The correlation between expression levels of multiple markers and prognosis will be evaluated.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Start Date
March 11, 2013
Primary Completion Date
October 31, 2024
Completion Date
December 31, 2024
Last Updated
January 16, 2024
100
ESTIMATED participants
Endoscopic biopsy
OTHER
Lead Sponsor
Seoul National University Bundang Hospital
NCT06226883
NCT07271069
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06975722